These results are consistent with the roles of EZH2 and MLL2 as poor prognosis factors in several types of cancers: while elevated activity of EZH2 is a poor prognosis indicator [75–79], impairing of MLL2 activity leads to poorer projected diagnosis [80–82]. Here, EZH2 is linked to cancer.